3 Stocks Pushing The Health Services Industry Lower
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.The Health Services industry as a whole closed the day down 0.2% versus the S&P 500, which was unchanged. Laggards within the Health Services industry included Dynatronics (DYNT), down 7.2%, Electromed (ELMD), down 2.6%, Pro-Dex (PDEX), down 6.1%, AxoGen (AXGN), down 3.0% and Retractable Technologies (RVP), down 3.2%.TheStreet Ratings Group would like to highlight 3 stocks that pushed the industry lower today:West Pharmaceutical Services (WST) is one of the companies that pushed the Health Services industry lower today. West Pharmaceutical Services was down $1.12 (2.5%) to $42.95 on light volume. Throughout the day, 204,969 shares of West Pharmaceutical Services exchanged hands as compared to its average daily volume of 287,000 shares. The stock ranged in price between $42.93-$44.14 after having opened the day at $44.10 as compared to the previous trading day's close of $44.07. West Pharmaceutical Services, Inc. develops, manufactures, and sells components and systems for the packaging and delivery of injectable drugs, as well as delivery system components for the pharmaceutical, healthcare, and consumer products industries. West Pharmaceutical Services has a market cap of $3.0 billion and is part of the health care sector. Shares are down 10.2% year-to-date as of the close of trading on Monday. Currently there is 1 analyst who rates West Pharmaceutical Services a buy, no analysts rate it a sell, and 1 rates it a hold.STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.TheStreet Ratings rates West Pharmaceutical Services as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow.Highlights from TheStreet Ratings analysis on WST go as follows:
- Despite its growing revenue, the company underperformed as compared with the industry average of 2.9%. Since the same quarter one year prior, revenues slightly increased by 2.2%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
- Compared to its closing price of one year ago, WST's share price has jumped by 30.41%, exceeding the performance of the broader market during that same time frame. We feel that the stock's sharp appreciation over the last year has driven it to a price level which is now somewhat expensive compared to the rest of its industry. The other strengths this company shows, however, justify the higher price levels.
- WEST PHARMACEUTICAL SVSC INC's earnings per share declined by 15.6% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, WEST PHARMACEUTICAL SVSC INC increased its bottom line by earning $1.58 versus $1.15 in the prior year. This year, the market expects an improvement in earnings ($1.83 versus $1.58).
- 36.97% is the gross profit margin for WEST PHARMACEUTICAL SVSC INC which we consider to be strong. Regardless of WST's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 7.81% trails the industry average.
- The change in net income from the same quarter one year ago has exceeded that of the Health Care Equipment & Supplies industry average, but is less than that of the S&P 500. The net income has decreased by 14.5% when compared to the same quarter one year ago, dropping from $31.70 million to $27.10 million.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV